

Navin Fluorine International (NFIL IN)

Management
Meet Update

May 25, 2026

■ Estimate Change | Target | ■ Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	ACCUMULATE		ACCUMULATE	
Target Price	7,489		7,297	
Sales (INR mn)	40,244	46,143	40,244	46,143
% Chng.	-	-	-	-
EBITDA (INR mn)	13,212	15,170	13,212	15,170
% Chng.	-	-	-	-
EPS (INR)	164.1	192.0	164.1	192.0
% Chng.	-	-	-	-

Key Data

NAFL.BO | NFIL IN

BSE Code	532504
NSE Code	NAVINFLUOR
52-W High / Low	INR 7,229 / INR 4,212
Face Value	2
Sensex / Nifty	75,415 / 23,719
Market Cap	INR 365 bn / \$ 3,819 mn
Shares Outstanding	51.29 mn
3M Avg. Daily Value	INR 1,594.46 mn

Shareholding Pattern (%)

Promoters	27.11
FIs	23.78
Mutual Funds	18.40
Domestic Institutions	5.38
Public & Others	25.33
Promoter's Pledge (INR bn)	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	13.7	9.2	19.3	64.9
Relative	18.4	19.9	34.8	77.0

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	23,494	33,139	40,244	46,143
EBITDA (INR mn)	5,337	10,817	13,212	15,170
Margin (%)	22.7	32.6	32.8	32.9
PAT (INR mn)	2,886	6,636	8,412	9,841
EV (INR mn)	367,402	376,451	371,462	364,950
Total Debt (INR mn)	14,407	12,264	11,037	9,933
C&C Eq. (INR mn)	405	969	4,731	10,139
EPS (INR)	58.2	129.5	164.1	192.0
Gr. (%)	32.0	122.5	26.8	17.0
DPS (INR)	12.0	13.3	16.7	19.5
Yield (%)	0.2	0.2	0.2	0.3
RoE (%)	11.5	20.1	19.3	19.0
RoCE (%)	10.6	20.1	20.7	21.3
EV/Sales (x)	15.6	11.4	9.2	7.9
EV/EBITDA (x)	68.8	34.8	28.1	24.1
PE (x)	122.5	55.0	43.4	37.1
P/BV (x)	13.5	9.2	7.7	6.5

Growth momentum Intact

Quick Pointers

- Management confident of achieving ~USD100mn CDMO revenue in FY27
- FY27 capex guidance of INR 7-9bn

We attended the analyst meet of Navin Fluorine International Ltd (NFIL) and, based on our interaction with the management, the company continues to remain well positioned for a strong multi-year growth trajectory across all three segments. The R32 equivalent capacity remains on track and is expected to commence operations in Q3FY27. Management indicated that demand for R32 remains robust, with limited downside risk to prices in the near term. The AHF capacity plays a critical role in strengthening downstream integration. The Chemours partnership, involving an initial investment of USD14mn, is now expected to commence by Jul-Aug'26, a slight delay compared to the earlier guidance of Q1FY27. The company has been producing pilot-scale samples over the past one year. Phase 2 capex could potentially scale up by nearly 10x as demand for liquid cooling fluids gains traction. Management also highlighted that demand for darolutamide, for which NFIL supplies a key intermediate, is expected to continue rising and will remain an important growth driver for the company. We expect revenue/EBITDA/PAT to register a CAGR of 18%/18%/22% over FY26-28E and maintain our 'Accumulate' rating on the stock with a target price of Rs7,489, valuing it at 39x FY28E EPS.

Limited downside risks to R32 pricing: The management reiterated that the ~15,000mtpa R32-equivalent capacity expansion project remains on track and is expected to commence operations in Q3FY27. Management also remains constructive on the R32 outlook, supported by healthy domestic demand and improving opportunities as a blend component. While domestic demand growth has moderated slightly compared to earlier elevated expectations. In China, domestic R32 demand has strengthened meaningfully, increasing by ~20-25ktpa YoY. Current domestic R32 capacities stand at ~9ktpa for Navin Fluorine International Ltd, ~25-30ktpa for SRF, and ~10ktpa for Gujarat Fluorochemicals, while Stallion India Fluorochemicals has recently commissioned an ~4ktpa capacity. Downside risk to R32 prices appears limited in near term.

Chemours project to come onstream by July-Aug'26: Project Nectar is expected to achieve ~75% utilization by end-FY27 and reach full utilization by FY28, with the dedicated portion of the project already operating at near full capacity. The Chemours project is likely to commence operations by Jul-Aug'26, reflecting a slight delay versus the earlier guided timeline of Q1FY27. Navin's facility will represent the first global manufacturing site for this product for Chemours. The company has been supplying pilot-scale quantities to Chemours over the past year, and the product has already received approvals from leading global customers. Management also indicated that the potential Phase II expansion for the Chemours project could be substantially larger, with capex estimated at nearly 10x the current investment of ~USD14mn, highlighting the sizeable long-term opportunity pipeline.

Strong CDMO pipeline and growth visibility: Management reiterated its confidence in achieving the CDMO segment revenue target of ~USD100mn by FY27. Over the past 2–3 years, the company has significantly diversified its product basket and now operates with a double-digit number of products across its CDMO pipeline. Management highlighted that 3–4 molecules have witnessed meaningful scale-up in recent quarters and have transitioned into advanced stages of commercialization. On darolutamide, management stated that the addressable market for Nubeqa is expected to expand further with additional approvals and entry into newer geographies. Darolutamide remains the only non-fluorine-based product in the portfolio, whereas the broader CDMO pipeline is largely driven by fluorine chemistry-based products.

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	23,494	33,139	40,244	46,143
YoY gr. (%)	13.8	41.1	21.4	14.7
Cost of Goods Sold	10,386	13,764	16,903	19,611
Gross Profit	13,108	19,375	23,342	26,532
Margin (%)	55.8	58.5	58.0	58.0
Employee Cost	2,967	3,073	3,288	3,518
Other Expenses	4,804	5,486	6,842	7,844
EBITDA	5,337	10,817	13,212	15,170
YoY gr. (%)	34.0	102.7	22.1	14.8
Margin (%)	22.7	32.6	32.8	32.9
Depreciation and Amortization	1,194	1,492	1,770	1,950
EBIT	4,143	9,325	11,442	13,219
Margin (%)	17.6	28.1	28.4	28.6
Net Interest	779	1,179	1,025	923
Other Income	437	653	724	738
Profit Before Tax	3,801	8,732	11,141	13,035
Margin (%)	16.2	26.3	27.7	28.2
Total Tax	915	2,096	2,730	3,194
Effective Tax Rate (%)	24.1	24.0	25.0	25.0
Profit After Tax	2,886	6,636	8,412	9,841
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	2,886	6,636	8,412	9,841
YoY gr. (%)	32.2	129.9	26.8	17.0
Margin (%)	12.3	20.0	20.9	21.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	2,886	6,636	8,412	9,841
YoY gr. (%)	32.2	129.9	26.8	17.0
Margin (%)	12.3	20.0	20.9	21.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	2,886	6,636	8,412	9,841
Equity Shares O/s (mn)	50	51	51	51
EPS (INR)	58.2	129.5	164.1	192.0

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	30,225	37,341	41,341	45,341
Tangibles	30,225	37,341	41,341	45,341
Intangibles	-	-	-	-
Acc: Dep / Amortization	4,721	6,213	7,983	9,933
Tangibles	4,721	6,213	7,983	9,933
Intangibles	-	-	-	-
Net Fixed Assets	25,505	31,128	33,358	35,408
Tangibles	25,505	31,128	33,358	35,408
Intangibles	-	-	-	-
Capital Work In Progress	3,498	1,433	1,433	1,433
Goodwill	-	-	-	-
Non-Current Investments	4,799	12,290	12,290	12,290
Net Deferred Tax Assets	(754)	(1,369)	(1,369)	(1,369)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	3,224	4,456	5,396	6,182
Trade Receivables	5,824	7,518	9,130	10,468
Cash & Bank Balance	405	969	4,731	10,139
Other Current Assets	5,048	5,998	5,998	5,998
Total Assets	48,304	63,791	72,335	81,918
Equity				
Equity Share Capital	99	103	103	103
Other Equity	26,163	39,643	47,199	56,040
Total Network	26,262	39,746	47,302	56,142
Non-Current Liabilities				
Long Term Borrowings	14,407	12,264	11,037	9,933
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade Payables	3,270	5,293	6,409	7,344
Other Current Liabilities	3,611	5,120	6,218	7,130
Total Equity & Liabilities	48,304	63,791	72,335	81,918

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	3,801	8,732	11,141	13,035
Add. Depreciation	1,194	1,492	1,770	1,950
Add. Interest	779	1,179	1,025	923
Less Financial Other Income	437	653	724	738
Add. Other	8	(303)	-	-
Op. Profit before WC Changes	5,783	11,099	13,937	15,908
Net Changes-WC	933	(382)	(337)	(279)
Direct Tax	(780)	(1,591)	(2,730)	(3,194)
Net Cash from Op. Activities	5,935	9,127	10,870	12,436
Capital Expenditures	(5,611)	(4,853)	(4,000)	(4,000)
Interest / Dividend Income	17	29	-	-
Others	484	(7,524)	-	-
Net Cash from Inv. Activities	(5,111)	(12,349)	(4,000)	(4,000)
Issue of Share Cap. / Premium	-	-	-	-
Debt Changes	1,014	1,447	(1,226)	(1,104)
Dividend Paid	(595)	(680)	(856)	(1,001)
Interest Paid	(786)	(1,056)	(1,025)	(923)
Others	-	-	-	-
Net Cash from Fin. Activities	(366)	(289)	(3,107)	(3,028)
Net Change in Cash	458	(3,511)	3,763	5,408
Free Cash Flow	324	4,274	6,870	8,436

Source: Company, PL

Quarterly Financials (INR mn)


Y/e Mar	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Net Revenues	7,254	7,584	8,924	9,377
YoY gr. (%)	38.5	46.3	47.2	33.8
Raw Material Expenses	3,077	3,129	3,677	3,881
Gross Profit	4,177	4,455	5,247	5,496
Margin (%)	57.6	58.7	58.8	58.6
EBITDA	2,068	2,462	3,076	3,212
YoY gr. (%)	106.1	129.3	108.8	79.7
Margin (%)	28.5	32.5	34.5	34.2
Depreciation / Depletion	352	366	362	412
EBIT	1,716	2,096	2,714	2,799
Margin (%)	23.6	27.6	30.4	29.9
Net Interest	304	303	283	289
Other Income	139	182	156	176
Profit before Tax	1,551	1,975	2,587	2,686
Margin (%)	21.4	26.0	29.0	28.6
Total Tax	379	491	529	697
Effective Tax Rate (%)	24.5	24.9	20.4	25.9
Profit After Tax	1,172	1,484	2,059	1,989
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,172	1,484	1,854	2,126
YoY gr. (%)	128.8	152.2	121.8	123.7
Margin (%)	16.2	19.6	20.8	22.7
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,172	1,484	1,854	2,126
YoY gr. (%)	128.8	152.2	121.8	123.7
Margin (%)	16.2	19.6	20.8	22.7
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	-	-	-	-
Avg. Shares O/s (mn)	50	50	50	50
EPS (INR)	23.4	29.7	37.1	42.5

Source: Company, PL

Key Financial Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	58.2	129.5	164.1	192.0
CEPS	82.3	158.6	198.7	230.1
BVPS	529.5	775.5	923.0	1,095.5
FCF	6.5	83.4	134.0	164.6
DPS	12.0	13.3	16.7	19.5
Return Ratio (%)				
RoCE	10.6	20.1	20.7	21.3
ROIC	8.1	15.5	16.5	18.2
RoE	11.5	20.1	19.3	19.0
Balance Sheet				
Net Debt : Equity (x)	0.5	0.3	0.1	-
Net Working Capital (Days)	90	74	74	74
Valuation (x)				
PER	122.4	55.0	43.4	37.1
P/B	13.4	9.1	7.7	6.5
P/CEPS	86.6	44.9	35.8	30.9
EV/EBITDA	68.8	34.8	28.1	24.0
EV/Sales	15.6	11.3	9.2	7.9
Dividend Yield (%)	0.1	0.1	0.2	0.2
FCFF Yield (%)	-	1.1	1.8	2.3
PEG Ratio	3.8	0.4	1.6	2.1

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	30-Apr-26	Accumulate	7297	6759
2	09-Apr-26	ACCUMULATE	6816	6062
3	19-Feb-26	Accumulate	7038	6387
4	09-Feb-26	Accumulate	7038	6598
5	07-Jan-26	Accumulate	6722	5751
6	20-Nov-25	Accumulate	6441	6025
7	14-Nov-25	Accumulate	6441	6015
8	30-Oct-25	Accumulate	5601	5009
9	07-Oct-25	Accumulate	5196	4568
10	31-Jul-25	Accumulate	5559	5198

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Aarti Industries	Accumulate	529	488
2	Bharat Petroleum Corporation	Accumulate	325	294
3	Bharti Airtel	BUY	2226	1884
4	Clean Science and Technology	Hold	846	818
5	Deepak Nitrite	REDUCE	1495	1749
6	Fine Organic Industries	BUY	5353	4607
7	GAIL (India)	Buy	190	161
8	Gujarat Fluorochemicals	HOLD	3316	3330
9	Gujarat Gas	Accumulate	342	313
10	Gujarat State Petronet	Hold	242	236
11	Hindustan Petroleum Corporation	Accumulate	427	390
12	Indian Oil Corporation	Accumulate	145	135
13	Indraprastha Gas	Buy	181	157
14	Jubilant Ingrevia	HOLD	657	635
15	Laxmi Organic Industries	REDUCE	143	152
16	Mahanagar Gas	Accumulate	1302	1174
17	Mangalore Refinery & Petrochemicals	Sell	143	186
18	Navin Fluorine International	Accumulate	7297	6759
19	NOCIL	HOLD	176	182
20	Oil & Natural Gas Corporation	Accumulate	309	287
21	Oil India	Accumulate	550	507
22	Petronet LNG	Accumulate	310	283
23	Reliance Industries	BUY	1635	1328
24	SRF	REDUCE	2579	2720
25	Sudeep Pharma	REDUCE	627	673
26	Vinati Organics	Accumulate	1475	1288

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.